The Supreme Court on Monday held that state-law design-defect claims that turn on the adequacy of a generic drug's warnings are preempted by federal law. Justice Samuel Alito authored the 5-4 decision in Mutual Pharmaceutical Company v. Bartlett, in which the Court reversed a First Circuit opinion that had affirmed a $21 million jury verdict against the generic drug manufacturer. In doing so, the Court rejected the plaintiff's attempt to circumvent the Court's ruling in PLIVA, Inc. v. Mensing, in which the Court held that state-law tort claims that challenge a generic drug's warnings are preempted by federal law. Goodwin Procter attorneys Richard Oetheimer and Jonathan Price were counsel for Petitioner Teva Pharmaceuticals USA, Inc ., in PLIVA.